|
|
||||||||
From the Department of Neurology (R.M.S., N.R.G., D.E.M., M.R., H.M.S., E.A.N., J.C.G.), University of Texas Houston Medical School; and Coordinating Center (S.B.), University of Texas School of Public Health.
Address correspondence and reprint requests to Dr. James C. Grotta, Director of the Stoke Department, Department of Neurology, The University of HoustonTexas, 6431 FanninMSB 7.128, Houston, TX 77030; e-mail: james.c.grotta{at}uth.tmc.edu
We report myocardial injury in 20 recombinant factor VIIa (rFVIIa) treated and 110 nontreated patients with intracerebral hemorrhage. Patients were treated or received standard medical management. All received EKG and cardiac enzyme testing. Elevated troponin occurred in 20% treated vs 3% nontreated (p = 0.02). Myocardial infarction occurred in 10% vs 1% (p = 0.01). We found a significant increase in myocardial injury in rFVIIa treated patients.
Editorial, see page 934
See also page 1096
R.M.S., M.R., and N.R.G. were supported by NIH training grant #T32NSO7412 to the University of Texas Houston Medical School Stroke Program.
Disclosure: The authors report no conflicts of interest.
Received February 15, 2006. Accepted in final form July 11, 2006.
Related articles in Neurology:
This article has been cited by other articles:
![]() |
H. Hallevi, N. R. Gonzales, A. D. Barreto, S. Martin-Schild, K. C. Albright, E. A. Noser, K. Illoh, A. M. Khaja, T. Allison, M. A. Escobar, et al. Response to Letter by Steiner et al Stroke, July 1, 2008; 39(7): e119 - e120. [Full Text] [PDF] |
||||
![]() |
P. S Owen, L. K Golightly, R. MacLaren, K. A Ferretti, and D. B Badesch Formulary Management of Recombinant Factor VIIa at an Academic Medical Center Ann. Pharmacother., June 1, 2008; 42(6): 771 - 776. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hallevi, N. R. Gonzales, A. D. Barreto, S. Martin-Schild, K. C. Albright, E. A. Noser, K. Illoh, A. M. Khaja, T. Allison, M. A. Escobar, et al. The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond 3 Hours Versus Within 3 Hours Stroke, February 1, 2008; 39(2): 473 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Mayer and on behalf of the FAST Trial Steering Committee COMPLICATIONS IN PATIENTS WITH INTRACEREBRAL HEMORRHAGE TREATED WITH RECOMBINANT FACTOR VIIA Neurology, July 17, 2007; 69(3): 319 - 320. [Full Text] [PDF] |
||||
![]() |
R. B. Libman, C. Lungu, and T. Kwiatkowski Multiple Ischemic Strokes Associated With Use of Recombinant Activated Factor VII Arch Neurol, June 1, 2007; 64(6): 879 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cruz-Flores, R. M. Sugg, and J. C. Grotta MYOCARDIAL INJURY IN PATIENTS WITH INTRACEREBRAL HEMORRHAGE TREATED WITH RECOMBINANT FACTOR VIIA Neurology, May 15, 2007; 68(20): 1750 - 1751. [Full Text] [PDF] |
||||
![]() |
S. M. Greenberg Is "compassionate use" compassionate?: rFVIIa for intracerebral hemorrhage. Neurology, September 26, 2006; 67(6): 934 - 935. [Full Text] [PDF] |
||||
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |